Format

Send to

Choose Destination
J Alzheimers Dis. 2016;49(2):271-6. doi: 10.3233/JAD-150405.

Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease.

Author information

1
Université catholique de Louvain, Brussels, Belgium.
2
Institute of Neuroscience, Brussels, Belgium.
3
Cliniques universitaires Saint Luc, Nuclear Medicine department, Brussels, Belgium.
4
Cliniques universitaires Saint Luc, Neurology department, Brussels, Belgium.

Abstract

We present the effects of Targretin® (bexarotene) on cognition and biomarkers in a patient with mild Alzheimer's disease (AD). Targretin® is a Retinoic X Receptor (RXR) agonist shown to improve synaptic and cognitive functions in animal models of AD by increasing neuronal cholesterol efflux. After 6 months of treatment with Targretin® 300 mg/day, memory improved by about 40% and the tau protein in the cerebrospinal fluid decreased by about 20% . No significant side effects were noticed. This observation in a single patient indicates that Targretin® may improve memory performance and biological markers at an early stage of AD.

KEYWORDS:

Amyloid-β and tau markers; Targretin/bexarotene; cholesterol; cognition

PMID:
26444777
DOI:
10.3233/JAD-150405
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center